Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.52NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BL.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BL.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23787.3US
BF.11.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BF.11.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.48NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.48NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JQ.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
JQ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.10.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.5.10.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BL.5NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BL.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-21588.8US
BA.5.2.23NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.5.2.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.1.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BE.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.4.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BF.7.4.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.5.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.5.5.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.37NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-21388.1US
BA.2.37NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.57NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.5.2.57NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CN.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CN.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.16NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.5.2.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.20NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BQ.1.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1.1.30NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CH.1.1.30NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.8NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.11NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BF.7.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CE.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CE.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1.1.25NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CH.1.1.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DB.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
DB.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1.1.16NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CH.1.1.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CZ.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CZ.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.18NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.5.1.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.29NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used